The Role of Omega-3 Fatty Acids in Neuroprotection: Molecular Mechanisms and Clinical Implications in Neurodegenerative Diseases. Focus on Alzheimer’s Disease, Multiple Sclerosis and Parkinson’s Disease
DOI:
https://doi.org/10.12775/QS.2025.47.66786Keywords
Omega 3 fatty acids, neurodegeneration, Alzheimer's disease, Parkinson's disease, multiple sclerosisAbstract
Among omega-3 fats, DHA and EPA stand out for their role in keeping the brain and nervous system healthy. Because the body cannot make sufficient amounts by itself, dietary intake is essential. These nutrients help nerve cells remain flexible and support smooth communication in the nervous system. While DHA is especially valuable for memory and mental performance, EPA, on the other hand, is mostly associated with managing brain inflammation.
Omega-3s protect nerve cells by easing inflammation and promoting cell survival. They also help damaged nerve tissue heal and encourage the growth of new brain cells, which supports clear thinking and learning. Certain substances derived from DHA and EPA help protect the brain from stress and cell loss.
Researchers have found that omega-3s may be useful for people dealing with Alzheimer’s, Parkinson’s and multiple sclerosis. In Alzheimer’s disease, these fats might preserve connections between brain cells. In Parkinson’s disease, they may assist with movement and nerve function. For people with MS, omega-3s could help by lowering inflammation and promoting the repair of nerve fibers. While omega-3s aren’t a cure, including them in the diet might help protect brain health and slow down the progression of the diseases.
References
1. Wysoczański T, Sokoła-Wysoczańska E, Pękala J, Lochyński S, Czyż K, Bodkowski R, et al. Omega-3 Fatty Acids and their Role in Central Nervous System - A Review. Curr Med Chem 2016;23:816–31. https://doi.org/10.2174/0929867323666160122114439.
2. Avallone R, Vitale G, Bertolotti M. Omega-3 Fatty Acids and Neurodegenerative Diseases: New Evidence in Clinical Trials. Int J Mol Sci 2019;20:4256. https://doi.org/10.3390/ijms20174256.
3. Calder PC. Omega‐3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol 2013;75:645–62. https://doi.org/10.1111/j.1365-2125.2012.04374.x.
4. Crupi R, Marino A, Cuzzocrea S. n-3 fatty acids: role in neurogenesis and neuroplasticity. Curr Med Chem 2013;20:2953–63. https://doi.org/10.2174/09298673113209990140.
5. Dighriri IM, Alsubaie AM, Hakami FM, Hamithi DM, Alshekh MM, Khobrani FA, et al. Effects of Omega-3 Polyunsaturated Fatty Acids on Brain Functions: A Systematic Review. Cureus n.d.;14:e30091. https://doi.org/10.7759/cureus.30091.
6. Ziaei S, Mohammadi S, Hasani M, Morvaridi M, Belančić A, Daneshzad E, et al. A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF). Nutr Neurosci 2024;27:715–25. https://doi.org/10.1080/1028415X.2023.2245996.
7. Healy Stoffel M, Levant b. N-3 (omega-3) fatty acids: effects on brain dopamine systems and potential role in the etiology and treatment of neuropsychiatric disorders. cns neurol disord drug targets 2018;17:216–32. https://doi.org/10.2174/1871527317666180412153612.
8. Kumar A, Singh A, Ekavali null. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep PR 2015;67:195–203. https://doi.org/10.1016/j.pharep.2014.09.004.
9. Canhada S, Castro K, Perry IS, Luft VC. Omega-3 fatty acids’ supplementation in Alzheimer’s disease: A systematic review. Nutr Neurosci 2018;21:529–38. https://doi.org/10.1080/1028415X.2017.1321813.
10. Deshmukh GV, Niaz H, Bai R, Kim DH, Kim JW, Asghar J, et al. The Role of Omega-3 Fatty Acid Supplementation in Slowing Cognitive Decline Among Elderly Patients With Alzheimer’s Disease: A Systematic Review of Randomized Controlled Trials. Cureus 2024;16:e73390. https://doi.org/10.7759/cureus.73390.
11. Kalamara TV, Dodos K, Georgakopoulou VE, Fotakopoulos G, Spandidos DA, Kapoukranidou D. Cognitive efficacy of omega‑3 fatty acids in Alzheimer’s disease: A systematic review and meta‑analysis. Biomed Rep 2025;22:1–7. https://doi.org/10.3892/br.2025.1940.
12. Ebright B, Duro MV, Chen K, Louie S, Yassine HN. Effects of APOE4 on omega-3 brain metabolism across the lifespan. Trends Endocrinol Metab 2024;35:745–57. https://doi.org/10.1016/j.tem.2024.03.003.
13. Shahinfar H, Yazdian Z, Avini NA, Torabinasab K, Shab-Bidar S. A systematic review and dose response meta analysis of Omega 3 supplementation on cognitive function. Sci Rep 2025;15:30610. https://doi.org/10.1038/s41598-025-16129-8.
14. Kouli A, Torsney KM, Kuan W-L. Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker TB, Greenland JC, editors. Park. Dis. Pathog. Clin. Asp., Brisbane (AU): Codon Publications; 2018.
15. Prajjwal P, Flores Sanga HS, Acharya K, Tango T, John J, Rodriguez RSC, et al. Parkinson’s disease updates: Addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment. Ann Med Surg 2012 2023;85:4887–902. https://doi.org/10.1097/MS9.0000000000001142.
16. Alves B da S, Schimith LE, da Cunha AB, Dora CL, Hort MA. Omega-3 polyunsaturated fatty acids and Parkinson’s disease: A systematic review of animal studies. J Neurochem 2024;168:1655–83. https://doi.org/10.1111/jnc.16154.
17. Calandria JM, Sharp MW, Bazan NG. The Docosanoid Neuroprotectin D1 Induces TH-Positive Neuronal Survival in a Cellular Model of Parkinson’s Disease. Cell Mol Neurobiol 2015;35:1127–36. https://doi.org/10.1007/s10571-015-0206-6.
18. Li P, Song C. Potential treatment of Parkinson’s disease with omega-3 polyunsaturated fatty acids. Nutr Neurosci 2022;25:180–91. https://doi.org/10.1080/1028415X.2020.1735143.
19. Chitre NM, Wood BJ, Ray A, Moniri NH, Murnane KS. Docosahexaenoic acid protects motor function and increases dopamine synthesis in a rat model of Parkinson’s disease via mechanisms associated with increased protein kinase activity in the striatum. Neuropharmacology 2020;167:107976. https://doi.org/10.1016/j.neuropharm.2020.107976.
20. Detopoulou P, Voulgaridou G, Saridaki A, Argyris E-M, Seva V, Dedes V, et al. Omega-3 fatty acids’ supplementation in Parkinson’s disease: A systematic review of randomized controlled trials. Clin Nutr Open Sci 2024;55:102–15. https://doi.org/10.1016/j.nutos.2024.03.007.
21. Taghizadeh M, Tamtaji OR, Dadgostar E, Daneshvar Kakhaki R, Bahmani F, Abolhassani J, et al. The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Neurochem Int 2017;108:183–9. https://doi.org/10.1016/j.neuint.2017.03.014.
22. Dighriri IM, Aldalbahi AA, Albeladi F, Tahiri AA, Kinani EM, Almohsen RA, et al. An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis. Cureus 2023;15:e33242. https://doi.org/10.7759/cureus.33242.
23. Mohammed EMA. Understanding Multiple Sclerosis Pathophysiology and Current Disease-Modifying Therapies: A Review of Unaddressed Aspects. Front Biosci Landmark Ed 2024;29:386. https://doi.org/10.31083/j.fbl2911386.
24. Golabi S, Robahat T, Madjdinasab N, Kamyari N, Naghashpour M. Omega-3 Fatty Acids Supplementation and Neuroprotection, Inflammation, Fatigue, and Physical Activity in Multiple Sclerosis: A Randomized Controlled Trial. Food Sci Nutr 2025;13:e70884. https://doi.org/10.1002/fsn3.70884.
25. Lin X, Zarghami A, Jelinek GA, Simpson-Yap S, Neate S, Nag N. Diet and omega-3 and vitamin D supplement use predict five-year fatigue and disability trajectories in people with multiple sclerosis. Mult Scler Relat Disord 2024;86:105615. https://doi.org/10.1016/j.msard.2024.105615.
26. AlAmmar WA, Albeesh FH, Ibrahim LM, Algindan YY, Yamani LZ, Khattab RY. Effect of omega-3 fatty acids and fish oil supplementation on multiple sclerosis: a systematic review. Nutr Neurosci 2021;24:569–79. https://doi.org/10.1080/1028415X.2019.1659560.
27. Aristotelous P, Stefanakis M, Pantzaris M, Pattichis CS, Calder PC, Patrikios IS, et al. The Effects of Specific Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins on Gait and Functional Capacity Parameters in Patients with Relapsing-Remitting Multiple Sclerosis. Nutrients 2021;13:3661. https://doi.org/10.3390/nu13103661.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mikołaj Patelski, Jakub Molenda, Maciej Czapla, Mateusz Surma, Barbara Pietrzak, Wiktoria Kotlarz, Marta Kamińska, Matylda Kuczma, Wiktoria Mikusek, Krzysztof Dobrzeniecki , Adrianna Klimczak

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 166
Number of citations: 0